Methods and reagents for the synthesis of nucleoside analogues, and uses thereof
The synthesis of ENAs through a fluorohydrin-dialkylsulfoxonium methylide reaction simplifies and reduces costs, addressing the inefficiencies of current methods and enhancing their therapeutic potential.
Patent Information
- Application Number
- PCT/IB2026/054726
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-15
- Filing Date
- 2026-05-12
- Publication Date
- 2026-11-19
AI Technical Summary
Current synthetic methods for ethylene-bridged nucleic acids (ENAs) are lengthy, complex, and low-yielding, leading to high production costs that limit their use in oligonucleotide therapeutics.
A method involving the reaction of a fluorohydrin compound with a dialkylsulfoxonium methylide to yield ethylene-bridged nucleic acid (ENA) compounds or intermediates, utilizing protecting groups to facilitate efficient synthesis.
The method simplifies and enhances the synthesis of ENAs, potentially reducing production costs and improving their availability for therapeutic applications.
Smart Images

Figure IB2026054726_19112026_PF_FP_ABST
Abstract
Description
10102-042W01METHODS AND REAGENTS FOR THE SYNTHESIS OF NUCLEOSIDE ANALOGUES,AND USES THEREOFFIELD
[0001] The present invention relates to methods for the synthesis of nucleoside analogues. More specifically, the present invention relates to methods for the synthesis of ethylene-bridged nucleic acids (ENAs).BACKGROUND
[0002] Nucleosides, the fundamental building blocks of DNA and RNA, play critical roles in processes such as energy transfer, cell signalling, and metabolism.[1ablSynthetic nucleoside analogues (NAs) have been instrumental in medicinal chemistry and chemical biology, acting as treatments for parasitic, bacterial, and fungal infections, and showing promise as potent anticancer drugs and epigenetic modulators.1231Modifications to the sugar, base, or phosphate moieties of NAs can improve their pharmacological properties, including nuclease resistance, binding affinity, and reduced toxicity.1451Despite challenges in synthesis, advancements in modified nucleic acid technology have led to pharmaceutical candidates with enhanced therapeutic effects.
[0003] These modifications include ethylene-bridged nucleic acid (ENA) monomers which can have high stability, enhanced binding affinity, and reduced hepatotoxicity compared to locked nucleic acid (LNA) monomers.1671ENA-modified antisense oligonucleotides (AONs) have shown potential in treating various diseases, including cancer, inflammation, and viral infections.18-131ENA-based oligonucleotides can exhibit enhanced nuclease resistance, binding affinity, and reduced toxicity.1141
[0004] Current synthetic methods for ENAs involve lengthy (13-17 steps), complex, and low-yielding chemical routes.16-81These inefficiencies lead to high production costs, limiting the use of ENAs in oligonucleotide therapeutics.SUMMARY
[0005] The present invention relates to methods and intermediates for the synthesis of ethylene-bridged nucleic acids (ENAs).
[0006] In one aspect, there is provided a method of synthesizing an ENA compound or intermediate thereof by providing a fluorohydrin of the structure:10102-042W01O OHOR1OR2Fwhere,R1and R2may each independently be H, alkyl, acyl, a hydroxyl protecting group, or together may be a cyclic protecting group; andR3may be an optionally substituted aryl or heteroaryl group; andreacting the fluorohydrin compound with a dialkylsulfoxonium methylide to yield an ENA compound or intermediate thereof of the structure:OR2where,R1and R2may each independently be H, alkyl, acyl, a hydroxyl protecting group, or together may be a cyclic protecting group; andR3may be an optionally substituted aryl or heteroaryl group.
[0007] In some embodiments, the dialkylsulfoxonium methylide compound may be (R4)2SOCH2 where R4may be Ci-Ce alkyl, such as dimethyloxosulfonium methylide.
[0008] In some embodiments, R1and R2may each independently be -OH or -OC(CH3)2O-.
[0009] In some embodiments, the fluorohydrin may be:whereR3may be an optionally substituted aryl or heteroaryl group; andZ may be H, alkyl, acyl, a hydroxyl protecting group, or a cyclic protecting group.
[0010] In some embodiments, the hydroxyl protecting group may be acetonide, silyl protecting group, alkyl protecting group or aryl protecting group.10102-042W01
[0011] In some embodiments, the fluorohydrin may be:, orwhere PG may be a protecting group.
[0012] In some embodiments, the method of synthesizing an ENA intermediate compound includes providing a fluorohydrin compound of the structure:where R3may be an optionally substituted aryl or heteroaryl group; andreacting the fluorohydrin compound with a dialkylsulfoxonium methylide to yield an ENA intermediate compound of the structure:where R3may be an optionally substituted aryl or heteroaryl group.10102-042W01
[0013] In some embodiments, the method of synthesizing an ENA compound includes providing an ENA intermediate compound of the structure:where R3may be an optionally substituted aryl or heteroaryl group; andreacting the ENA intermediate compound with a suitable reagent to yield an ENA triol compound of the structure:OHwhere R3may be an optionally substituted aryl or heteroaryl group.
[0014] In some embodiments, the ENA intermediate compound may be:
[0015] In some aspects, there is provided a method of synthesizing an ENA triol compound by providing an ENA intermediate compound of the structure:10102-042W01where R3may be an optionally substituted aryl or heteroaryl group; andreacting the ENA intermediate compound with a suitable reagent to yield an ENA triol compound of the structure:OHwhere R3may be an optionally substituted aryl or heteroaryl group.
[0016] In some embodiments, the suitable reagent may be a Bronsted-Lowry acid or a Lewis acid.
[0017] In some embodiments, R3may be an optionally substituted purine or an optionally substituted pyrimidine group.
[0018] In some embodiments, R3may be an optionally substituted purine-9-yl or an optionally substituted 2-oxo-l,2-dihydropyrimidine-l-yl group.
[0019] In some embodiments, the ENA intermediate compound may be:10102-042W01
[0020] In some aspects, there is provided a compound of the structure:
[0021] This summary does not necessarily describe all features of the invention.10102-042W01DETAILED DESCRIPTION
[0022] The present disclosure provides, in part, methods for the synthesis of ethylene-bridged nucleic acids (ENAs).
[0023] In some embodiments, the present disclosure provides a method for nucleoside synthesis that utilizes a fluorohydrin compound1151to produce an aceton ide-protected (AP) nucleic acid. Without being bound to any particular hypothesis, the protecting group in acetonide-protected (AP) NAs may impose a strain that drives an RNA-like (North) conformation, which may allow for efficient synthesis of ENAs.
[0024] Accordingly, in one aspect, the present disclosure provides a method of synthesizing an ENA compound or intermediate thereof by providing a fluorohydrin of the structure:O OHOR1OR2FwhereR1and R2can each independently be H, alkyl, acyl, a hydroxyl protecting group, or together may be a cyclic protecting group; andR3can be an optionally substituted aryl or heteroaryl group;and reacting the fluorohydrin compound with a dialkylsulfoxonium methylide to yield an ENA compound or intermediate thereof of the structure:whereR1and R2can each independently be H, alkyl, acyl, a hydroxyl protecting group, or together may be a cyclic protecting group; andR3can be an optionally substituted aryl or heteroaryl group.
[0025] In an alternative aspect, the present disclosure provides a method of synthesizing an ENA triol compound by providing an ENA intermediate compound of the structure:10102-042W01where R3can be an optionally substituted aryl or heteroaryl group;and reacting the ENA intermediate compound with a suitable reagent, to yield an ENA triol compound of the structure:OHwhere R3can be an optionally substituted aryl or heteroaryl group.
[0026] In some embodiments, the dialkylsulfoxonium methylide compound can be (R4)2SOCH2where R4can be Ci-Ce alkyl.
[0027] In some embodiments, R1and R2can each independently be -OH or -OC(CH3)2O-.
[0028] In some embodiments, the fluorohydrin can be:whereR3can be an optionally substituted aryl or heteroaryl group; andZ can be H, alkyl, acyl, a hydroxyl protecting group, or a cyclic protecting group.
[0029] In some embodiments, the hydroxyl protecting group can be acetonide, silyl protecting group, alkyl protecting group or aryl protecting group.
[0030] In some embodiments, R3may be an optionally substituted purine or an optionally substituted pyrimidine group.
[0031] In some embodiments, R3may be an optionally substituted purine-9-yl or an optionally substituted 2-oxo-l,2-dihydropyrimidine-l-yl group.
[0032] In some embodiments, Ri can be H.10102-042W01
[0033] In some embodiments, Ri can be alkyl.
[0034] In some embodiments, Ri can be acyl.
[0035] In some embodiments, Ri can be a hydroxyl protecting group.
[0036] In some embodiments, R2can be H.
[0037] In some embodiments, R2can be alkyl.
[0038] In some embodiments, R2can be acyl.
[0039] In some embodiments, R2can be a hydroxyl protecting group.
[0040] In some embodiments, Ri and R2 together can form a cyclic protecting group.
[0041] In some embodiments, R3 can be an optionally substituted purine group.
[0042] In some embodiments, R3 can be an optionally substituted pyrimidine group.
[0043] In some embodiments, R3may be an optionally substituted purine-9-yl group.
[0044] In some embodiments, R3may be an optionally substituted 2-oxo-l,2-dihydropyrimidine-l-yl group.
[0045] In some embodiments, Ri can be H, R2can be H.
[0046] In some embodiments, Ri can be H; R2can be alkyl.
[0047] In some embodiments, Ri can be H; R2can be acyl.
[0048] In some embodiments, Ri can be H; R2can be a hydroxyl protecting group.
[0049] In some embodiments, Ri can be alkyl; R2can be H.
[0050] In some embodiments, Ri can be alkyl; R2can be alkyl.
[0051] In some embodiments, Ri can be alkyl; R2can be acyl.
[0052] In some embodiments, Ri can be alkyl; R2can be a hydroxyl protecting group
[0053] In some embodiments, Ri can be acyl; R2can be H.
[0054] In some embodiments, Ri can be acyl; R2can be alkyl.
[0055] In some embodiments, Ri can be acyl; R2can be acyl.
[0056] In some embodiments, Ri can be acyl; R2can be a hydroxyl protecting group.
[0057] In some embodiments, Ri can be a hydroxyl protecting group; R2can be H.
[0058] In some embodiments, Ri can be a hydroxyl protecting group; R2can be alkyl
[0059] In some embodiments, Ri can be a hydroxyl protecting group; R2can be acyl.10102-042W01
[0060] In some embodiments, Ri can be a hydroxyl protecting group; R2can be a hydroxyl protecting group.
[0061] In some embodiments, Ri can be H; R2can be H; R3can be an optionally substituted aryl group.
[0062] In some embodiments, Ri can be H; R2can be alkyl; R3can be an optionally substituted aryl group.
[0063] In some embodiments, Ri can be H; R2can be acyl; R3can be an optionally substituted aryl group.
[0064] In some embodiments, Ri can be H; R2can be a hydroxyl protecting group; R3can be an optionally substituted aryl group.
[0065] In some embodiments, Ri can be alkyl; R2can be H; R3can be an optionally substituted aryl group.
[0066] In some embodiments, Ri can be alkyl; R2can be alkyl; R3can be an optionally substituted aryl group.
[0067] In some embodiments, Ri can be alkyl; R2can be acyl; R3can be an optionally substituted aryl group.
[0068] In some embodiments, Ri can be alkyl; R2can be a hydroxyl protecting group; R3can be an optionally substituted aryl group.
[0069] In some embodiments, Ri can be acyl; R2can be H; R3can be an optionally substituted aryl group.
[0070] In some embodiments, Ri can be acyl; R2can be alkyl; R3can be an optionally substituted aryl group.
[0071] In some embodiments, Ri can be acyl; R2can be acyl; R3can be an optionally substituted aryl group.
[0072] In some embodiments, Ri can be acyl; R2can be a hydroxyl protecting group; R3can be an optionally substituted aryl group.
[0073] In some embodiments, Ri can be a hydroxyl protecting group; R2can be H; R3can be an optionally substituted aryl group.
[0074] In some embodiments, Ri can be a hydroxyl protecting group; R2can be alkyl; R3can be an optionally substituted aryl group.
[0075] In some embodiments, Ri can be a hydroxyl protecting group; R2can be acyl; R3can be an optionally substituted aryl group.10102-042W01
[0076] In some embodiments, Ri can be a hydroxyl protecting group; R2can be a hydroxyl protecting group; R3 can be an optionally substituted aryl group.
[0077] In some embodiments, R1 and R2 together can form a cyclic protecting group; R3 can be an optionally substituted aryl group.
[0078] In some embodiments, R1 can be H; R2can be H; R3can be an optionally substituted heteroaryl group.
[0079] In some embodiments, R1 can be H; R2can be alkyl; R3can be an optionally substituted heteroaryl group.
[0080] In some embodiments, R1 can be H; R2can be acyl; R3 can be an optionally substituted heteroaryl group.
[0081] In some embodiments, R1 can be H; R2can be a hydroxyl protecting group; R3 can be an optionally substituted heteroaryl group.
[0082] In some embodiments, R1 can be alkyl; R2can be H; R3can be an optionally substituted heteroaryl group.
[0083] In some embodiments, R1 can be alkyl; R2can be alkyl; R3can be an optionally substituted heteroaryl group.
[0084] In some embodiments, R1 can be alkyl; R2can be acyl; R3 can be an optionally substituted heteroaryl group.
[0085] In some embodiments, R1 can be alkyl; R2can be a hydroxyl protecting group; R3 can be an optionally substituted heteroaryl group.
[0086] In some embodiments, R1 can be acyl; R2can be H; R3can be an optionally substituted heteroaryl group.
[0087] In some embodiments, R1 can be acyl; R2can be alkyl; R3can be an optionally substituted heteroaryl group.
[0088] In some embodiments, R1 can be acyl; R2can be acyl; R3 can be an optionally substituted heteroaryl group.
[0089] In some embodiments, R1 can be acyl; R2can be a hydroxyl protecting group; R3 can be an optionally substituted heteroaryl group.
[0090] In some embodiments, R1 can be a hydroxyl protecting group; R2can be H; R3can be an optionally substituted heteroaryl group.
[0091] In some embodiments, R1 can be a hydroxyl protecting group; R2can be alkyl; R3can be an optionally substituted heteroaryl group.10102-042W01
[0092] In some embodiments, Ri can be a hydroxyl protecting group; R2can be acyl; R3 can be an optionally substituted heteroaryl group.
[0093] In some embodiments, R1 can be H; R2can be H; R3can be an optionally substituted purine group.
[0094] In some embodiments, R1 can be H; R2can be alkyl; R3can be an optionally substituted purine group.
[0095] In some embodiments, R1 can be H; R2can be acyl; R3can be an optionally substituted purine group.
[0096] In some embodiments, R1 can be H; R2can be a hydroxyl protecting group; R3can be an optionally substituted purine group.
[0097] In some embodiments, R1 can be alkyl; R2can be H; R3can be an optionally substituted purine group.
[0098] In some embodiments, R1 can be alkyl; R2can be alkyl; R3can be an optionally substituted purine group.
[0099] In some embodiments, R1 can be alkyl; R2can be acyl; R3can be an optionally substituted purine group.
[0100] In some embodiments, R1 can be alkyl; R2can be a hydroxyl protecting group; R3can be an optionally substituted purine group.
[0101] In some embodiments, R1 can be acyl; R2can be H; R3can be an optionally substituted purine group.
[0102] In some embodiments, R1 can be acyl; R2can be alkyl; R3can be an optionally substituted purine group.
[0103] In some embodiments, R1 can be acyl; R2can be acyl; R3can be an optionally substituted purine group.
[0104] In some embodiments, R1 can be acyl; R2can be a hydroxyl protecting group; R3can be an optionally substituted purine group.
[0105] In some embodiments, R1 can be a hydroxyl protecting group; R2can be H; R3can be an optionally substituted purine group.
[0106] In some embodiments, R1 can be a hydroxyl protecting group; R2can be alkyl; R3can be an optionally substituted purine group.
[0107] In some embodiments, R1 can be a hydroxyl protecting group; R2can be acyl; R3can be an optionally substituted purine group.10102-042W01
[0108] In some embodiments, Ri can be a hydroxyl protecting group; R2can be a hydroxyl protecting group; R3 can be an optionally substituted purine group.
[0109] In some embodiments, R1 and R2 together can form a cyclic protecting group; R3 can be an optionally substituted purine group.
[0110] In some embodiments, R1 can be H; R2can be H; R3can be an optionally substituted pyrimidine group.
[0111] In some embodiments, R1 can be H; R2can be alkyl; R3can be an optionally substituted pyrimidine group.
[0112] In some embodiments, R1 can be H; R2can be acyl; R3 can be an optionally substituted pyrimidine group.
[0113] In some embodiments, R1 can be H; R2can be a hydroxyl protecting group; R3 can be an optionally substituted pyrimidine group.
[0114] In some embodiments, R1 can be alkyl; R2can be H; R3can be an optionally substituted pyrimidine group.
[0115] In some embodiments, R1 can be alkyl; R2can be alkyl; R3can be an optionally substituted pyrimidine group.
[0116] In some embodiments, R1 can be alkyl; R2can be acyl; R3 can be an optionally substituted pyrimidine group.
[0117] In some embodiments, R1 can be alkyl; R2can be a hydroxyl protecting group; R3 can be an optionally substituted pyrimidine group.
[0118] In some embodiments, R1 can be acyl; R2can be H; R3can be an optionally substituted pyrimidine group.
[0119] In some embodiments, R1 can be acyl; R2can be alkyl; R3can be an optionally substituted pyrimidine group.
[0120] In some embodiments, R1 can be acyl; R2can be acyl; R3 can be an optionally substituted pyrimidine group.
[0121] In some embodiments, R1 can be acyl; R2can be a hydroxyl protecting group; R3 can be an optionally substituted pyrimidine group.
[0122] In some embodiments, R1 can be a hydroxyl protecting group; R2can be H; R3can be an optionally substituted pyrimidine group.
[0123] In some embodiments, R1 can be a hydroxyl protecting group; R2can be alkyl; R3 can be an optionally substituted pyrimidine group.10102-042W01
[0124] In some embodiments, Ri can be a hydroxyl protecting group; R2can be acyl; R3 can be an optionally substituted pyrimidine group.
[0125] In some embodiments, R1 can be H; R2can be H; R3can be an optionally substituted purine-9-yl group.
[0126] In some embodiments, R1 can be H; R2can be alkyl; R3can be an optionally substituted purine-9-yl group.
[0127] In some embodiments, R1 can be H; R2can be acyl; R3can be an optionally substituted purine-9-yl group.
[0128] In some embodiments, R1 can be H; R2can be a hydroxyl protecting group; R3can be an optionally substituted purine-9-yl group.
[0129] In some embodiments, R1 can be alkyl; R2can be H; R3can be an optionally substituted purine-9-yl group.
[0130] In some embodiments, R1 can be alkyl; R2can be alkyl; R3can be an optionally substituted purine-9-yl group.
[0131] In some embodiments, R1 can be alkyl; R2can be acyl; R3can be an optionally substituted purine-9-yl group.
[0132] In some embodiments, R1 can be alkyl; R2can be a hydroxyl protecting group; R3can be an optionally substituted purine-9-yl group.
[0133] In some embodiments, R1 can be acyl; R2can be H; R3can be an optionally substituted purine-9-yl group.
[0134] In some embodiments, R1 can be acyl; R2can be alkyl; R3can be an optionally substituted purine-9-yl group.
[0135] In some embodiments, R1 can be acyl; R2can be acyl; R3can be an optionally substituted purine-9-yl group.
[0136] In some embodiments, R1 can be acyl; R2can be a hydroxyl protecting group; R3can be an optionally substituted purine-9-yl group.
[0137] In some embodiments, R1 can be a hydroxyl protecting group; R2can be H; R3can be an optionally substituted purine-9-yl group.
[0138] In some embodiments, R1 can be a hydroxyl protecting group; R2can be alkyl; R3can be an optionally substituted purine-9-yl group.
[0139] In some embodiments, R1 can be a hydroxyl protecting group; R2can be acyl; R3can be an optionally substituted purine-9-yl group.10102-042W01
[0140] In some embodiments, Ri can be a hydroxyl protecting group; R2can be a hydroxyl protecting group; R3 can be an optionally substituted purine-9-yl group.
[0141] In some embodiments, R1 and R2 together can form a cyclic protecting group; R3 can be an optionally substituted purine-9-yl group.
[0142] In some embodiments, R1 can be H; R2can be H; R3can be an optionally substituted 2-oxo-l,2-dihydropyrimidine-l-yl group.
[0143] In some embodiments, R1 can be H; R2can be alkyl; R3can be an optionally substituted 2-oxo-l,2-dihydropyrimidine-l-yl group.
[0144] In some embodiments, R1 can be H; R2can be acyl; R3 can be an optionally substituted 2-oxo-l,2-dihydropyrimidine-l-yl group.
[0145] In some embodiments, R1 can be H; R2can be a hydroxyl protecting group; R3 can be an optionally substituted 2-oxo-l,2-dihydropyrimidine-l-yl group.
[0146] In some embodiments, R1 can be alkyl; R2can be H; R3can be an optionally substituted 2-oxo-l,2-dihydropyrimidine-l-yl group.
[0147] In some embodiments, R1 can be alkyl; R2can be alkyl; R3can be an optionally substituted 2-oxo-l,2-dihydropyrimidine-l-yl group.
[0148] In some embodiments, R1 can be alkyl; R2can be acyl; R3 can be an optionally substituted 2-oxo-l,2-dihydropyrimidine-l-yl group.
[0149] In some embodiments, R1 can be alkyl; R2can be a hydroxyl protecting group; R3 can be an optionally substituted 2-oxo-l,2-dihydropyrimidine-l-yl group.
[0150] In some embodiments, R1 can be acyl; R2can be H; R3can be an optionally substituted 2-oxo-l,2-dihydropyrimidine-l-yl group.
[0151] In some embodiments, R1 can be acyl; R2can be alkyl; R3can be an optionally substituted 2-oxo-l,2-dihydropyrimidine-l-yl group.
[0152] In some embodiments, R1 can be acyl; R2can be acyl; R3 can be an optionally substituted 2-oxo-l,2-dihydropyrimidine-l-yl group.
[0153] In some embodiments, R1 can be acyl; R2can be a hydroxyl protecting group; R3 can be an optionally substituted 2-oxo-l,2-dihydropyrimidine-l-yl group.
[0154] In some embodiments, R1 can be a hydroxyl protecting group; R2can be H; R3can be an optionally substituted 2-oxo-l,2-dihydropyrimidine-l-yl group.
[0155] In some embodiments, R1 can be a hydroxyl protecting group; R2can be alkyl; R3 can be an optionally substituted 2-oxo-l,2-dihydropyrimidine-l-yl group.10102-042W01
[0156] In some embodiments, Ri can be a hydroxyl protecting group; F^can be acyl; R3 can be an optionally substituted 2-oxo-l,2-dihydropyrimidine-l-yl group.
[0157] In some embodiments, the fluorohydrin compound can be:, orwhere PG is a protecting group.
[0158] In some embodiments, the ENA triol compound can be prepared from the fluorohydrin compound in a “one-pot” process.
[0159] In some embodiments, the suitable reagent can be a Bronsted-Lowry acid or a Lewis acid.
[0160] In alternatives aspects, there is provided an ENA intermediate compound:where R3can be an optionally substituted aryl or heteroaryl group.
[0161] In some embodiments, the ENA intermediate compound can be:10102-042W01
[0162] In some embodiments of the various aspects described herein, R1and R2can each independently be -OH or -OC(CH3)2O-.
[0163] In some embodiments of the various aspects described herein, R3can be an optionally substituted purine-9-yl group or an optionally substituted 2-oxo-l,2-dihydropyrimidine-l-yl group.
[0164] By “nucleoside” is meant a glycosylamine having a nitrogenous base or “nucleobase” or “NB” and a sugar ring (e.g., ribose or deoxyribose), in which the anomeric carbon is linked through a glycosidic bond to the N9 of a purine {e.g., adenine or guanine) or the N1 of a pyrimidine e.g., cytosine, thymine, or uracil). Nucleosides include both L- and D-nucleoside isomers. Examples of nucleosides include cytidine, uridine, adenosine, guanosine, thymidine and inosine.
[0165] Nucleoside analogues (NAs) are compounds that are structurally similar to naturally occurring nucleosides. NAs can include, without limitation, compounds with modifications or “functionalizations” at positions CT, C2', C3', C4' and / or C5' of the sugar ring, relative to a naturally occurring nucleoside. In some embodiments, NAs can exist as a free triol or may be phosphorylated at C3' and / or C5'. In some embodiments, NAs can include, without limitation, compounds with a saturated or unsaturated carbocyclic ring. In some embodiments, NAs can include nitrogen or sulphur in the sugar ring, for example as a replacement for the naturally occurring oxygen, and / or can include N-R groups, where R can be without limitation alkyl, allyl, alkynyl or benzyl. In some embodiments, the nucleoside10102-042W01analogues disclosed herein can be modified to function as a phosphoramidate or phosphonamidate compound, e.g., a “ProTide,” which includes a 5'-nucleoside monophosphate in which the two hydroxyl groups are masked with an amino acid ester and an aryloxy component which can be enzymatically metabolized to deliver free 5'-monophosphate, which is further transformed to the active 5'-triphosphate form of the nucleoside analogue, once delivered to a cell.
[0166] The “NB” or nucleobase of an NA can be any aryl or heteroaryl attached from the C1 position to a carbon or nitrogen atom. NBs can also be modified, for example, can be 5,6-dihydrouracil, 5-methylcytosine, 5-hydroxymethylcytosine, 5,5,5-trifluoromethylthymine, 5-fluorouracil, 2-thiouracil, 4-methylbenzimidazole, hypoxanthine, 7-deazaguanine, 7-deazaadenine, indole, imidazole, triazole, pyrrole, pyrazole, etc.
[0167] An “ethylene-bridged nucleic acid” or “ENA,” as used herein, refers to an NA in which the oxygen at the C2' position is connected by an ethylene to C4'. In some embodiments, an ENA can be acetonide-protected (AP-ENA). In some embodiments, an ENA can be an ENA triol compound.
[0168] By “acetonide” is meant a group composed of the cyclic ketal of a diol with acetone.
[0169] “Alkyl” refers to a straight or branched hydrocarbon chain group consisting solely of carbon and hydrogen atoms, containing no unsaturation and including, for example, from one to ten carbon atoms, or any value in between, such as 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, and which is attached to the rest of the molecule by a single bond. In some embodiments, alkyl can refer to a straight or branched hydrocarbon chain group consisting solely of carbon and hydrogen atoms, containing no unsaturation and including from one to six carbon atoms, or any value in between, such as 1 , 2, 3, 4, 5, or 6 carbon atoms, and which is attached to the rest of the molecule by a single bond. Unless stated otherwise specifically in the specification, the alkyl group can be optionally substituted by one or more substituents as described herein, for example, oxygen. For example, alkyl can include, without limitation, C1-10 alkoxy. Unless stated otherwise specifically herein, it is understood that the substitution can occur on any carbon of the alkyl group.
[0170] By “acyl,” as used herein, refers to a radical formed by removal of a hydroxyl group from an organic acid and is meant a group having the structure C(O) Rt>, where Rb may be aliphatic, alicyclic or aromatic. Examples include aliphatic carbonyls, aromatic carbonyls, aliphatic sulfonyls, aromatic sulfinyls, aliphatic sulfinyls, aromatic phosphates, aliphatic phosphates and the like. Unless stated otherwise specifically herein, the term “acyl” is meant to include acyl groups optionally substituted by one or more substituents as described herein.
[0171] By “aryl” is meant a monocyclic or bicyclic aromatic ring containing only carbon atoms, including for example, 5-14 members, such as 5, 6, 7, 8, 9, 10, 11, 12, 13, or10102-042W0114 members. Examples of aryl groups include phenyl, biphenyl, naphthyl, indanyl, indenyl, tetrahydronaphthyl, 2,3-dihydrobenzofuranyl, dihydrobenzopyranyl, 1 ,4-benzodioxanyl, and the like. Unless stated otherwise specifically herein, the term “aryl” is meant to include aryl groups optionally substituted by one or more substituents as described herein.
[0172] “Heteroaryl” refers to a single or fused aromatic ring group containing one or more heteroatoms in the ring, for example N, O, S, including for example, 5-14 members, such as 5, 6, 7, 8, 9, 10, 11 , 12, 13, or 14 members. Examples of heteroaryl groups include furan, thiophene, pyrrole, oxazole, thiazole, imidazole, pyrazole, isoxazole, isothiazole, 1 ,2,3-oxadiazole, triazole e.g., 1,2,3-triazole or 1 ,2,4-triazole), 1 ,3,4-thiadiazole, tetrazole, pyrazole, pyridine, pyridazine, pyrimidine, 2,6-dichloropyrimidine pyrazine, 1 ,3,5-triazine, imidazole, benzimidazole, benzoxazole, benzothiazole, indolizine, indole, isoindole, benzofuran, benzothiophene, 1H-indazole, purine, 4H-quinolizine, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, quinoxaline, 1 ,8-naphthyridine, pteridine, uracil, thymine, deazadenine, phthalimide, adenine, and the like. Unless stated otherwise specifically herein, the term “heteroaryl” is meant to include heteroaryl groups optionally substituted by one or more substituents as described herein.
[0173] Halogens include bromine, chlorine, fluorine, iodine, etc. In some embodiments, a halogen can include chlorine or fluorine. According, “halo” refers to bromo, chloro, fluoro, iodo, etc. A halide is a halogen atom bearing a negative charge.
[0174] A “protecting group” as used herein, means a labile chemical moiety i.e., a reversibly formed derivative of an existing functional group in a molecule that is temporarily attached to decrease reactivity such that the protected functional group does not react under synthetic conditions to which the molecule is subjected in one or more subsequent steps. It is to be understood that a person skilled in the art will readily be able to determine a suitable protecting group for a particular synthesis. In some embodiments, a protecting group can be a cyclic protecting group. In some embodiments, a protecting group can include, without limitation, a carbamate, acyl, silyl, ketal, acetal, acetonide, or a disiloxane group. A protecting group includes, without limitation, hydroxyl groups, amino groups, thiol groups, benzyl (Bn) groups, benzoyl (Bz) groups, t-butyl carbamate (Boc) groups, benzyl carbamate (CBZ) groups, p-methoxybenzyl (PMB) groups, substituted silanes (TMS, TBS, TBDMS, TIPS), acetyl (Ac) groups, benzyloxymethyl (BOM) groups, methyloxymethyl (MOM) groups, tetrahydropyranyl (THP) groups, trityl (Tr) groups, dimethoxytrityl (DMT) groups, pivaloyl (Piv) groups, t-butyl ether (tBu) groups, tosyl (Ts) groups, allyl (Al) groups, benzyl esters, t-butyl esters or dimethyl acetonide groups. In some embodiments a protecting group is a benzoyl group. In some embodiments a protecting group is 2-methylpropionyl. Protecting groups are as described herein or as known in the art. Protecting groups as known in the art are described generally in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M.10102-042W01Wuts, 3rd edition, John Wiley & Sons, 1999. Protecting groups adapted for nucleoside and nucleotide chemistry are as described in Chapter 2, Current Protocols in Nucleic Acid Chemistry, edited by Serge L. Beaucage etal. 06 / 2012.
[0175] In some embodiments, a “hydroxyl protecting group” or “suitable alcohol protecting group” or an “alcohol protecting group” includes, without limitation, a suitable ether, for example, a phenylmethyl or trimethylsilyl ether; a suitable ester, or a suitable acetal. A hydroxyl protecting group includes, without limitation, acetonide, silyl protecting group, alkyl protecting group or aryl protecting group (including cyclic or acyclic), such as a silyl ether for example, tert-butyl(dimethyl)s / 7y / (TBS), triisopropylsilyl (TIPS), trimethylsilyl (TMS), tert-butyldiphenylsilyl (TBDPS), triethylsilyl (TES), 2-(trimethylsilyl)ethoxymethyl ether (SEM), etc.; acetate (Ac), pivalate (Piv) or other ester or carbonate protecting group etc.; benzyl, allyl, methoxymethyl or p-methoxybenzyl (PMB) or other ether protecting group, etc.; tetrahydropyranyl (THP) ether, methyl, methoxylmethyl (MOM), methylthiomethyl (MTM), t-butylthiomethyl, (phenyldimethylsilyl) methoxymethyl (SMOM), benzyloxymethyl (BOM), p-methoxybenzyloxymethyl (PMBM), (4-methoxyphe noxy)methyl (p-AOM), guaiacolmethyl (GUM), t-butoxym ethyl, 4-pentenyloxymethyl (POM), siloxymethyl, 2-methoxyethoxymethyl (MEM), 2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl, 2-(trimethylsilyl) ethoxymethyl (SEMOR), tetrahydropyranyl (THP), 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 1 -methoxycyclohexyl, 4-methoxytetrahydropyranyl (MTHP), 4-methoxytetrahydrothiopyranyl, 4-methoxytetra hydrothiopyranyl S,S-dioxide, 1-[(2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl (CTMP), 1 ,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl, 2, 3, 3a, 4, 5, 6, 7, 7a octahydro-7, 8, 8-trimethyl-4,7-methanobenzofuran-2-yl, 1 -ethoxyethyl, 1-(2-chloroethoxy)ethyl, 1-methyl-1 -methoxyethyl, 1-methyl-1-benzyloxyethyl, 1 -methyl -1 -ben zyloxy-2-fluoroethyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-(phenylselenyl)ethyl, t-butyl, allyl, p-chlorophenyl, p-methoxyphenyl, 2,4-dinitrophenyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2-picolyl, 4-picolyl, 3-methyl-2-picolyl N-oxido, diphenylmethyl, p,p'-dinitrobenzhydryl 5-dibenzosuberyl, triphenylmethyl, a-naphthyldiphenylmethyl, p-methoxyphenyldiphenylmethyl, di(p-methoxyphenyl)phenylmethyl, tri(p-methoxyphenyl)methyl, 4-(4'-bromophenacyloxyphenyl) diphenylmethyl, 4,4',4"-tris(4,5-dichlorophthalimidophenyl)methyl, 4,4',4"-tris(levulinoyloxyphenyl)methyl, 4,4',4"-tris (benzoyloxyphenyl)methyl, 3-(imidazol-1-yl)bis(4',4"-dimethoxyphenyl)methyl, 1 , 1 -bis(4-methoxyphenyl)-1'-pyrenylmethyl, 9-anthryl, 9-(9-phenyl)xanthenyl, 9-(9- pheny 1-10-oxo)anthryl, 1 ,3-benzodithiolan-2-yl, benzisothiazolyl S,S-dioxido, trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), dimethylisopropylsilyl (IPDMS), diethylisopropylsilyl (DEIPS), dimethylthexylsilyl, t-butyldimethylsilyl (TBDMS), t-butyldiphenylsilyl (TBDPS), tribenzylsilyl, tri-p-xylylsilyl, triphenylsilyl, diphenylmethylsilyl (DPMS), t-10102-042W01butylmethoxyphenylsilyl (TBMPS), formate, benzoylformate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4-oxopentanoate (levulinate), 4,4-(ethylenedithio)pentanoate (levulinoyldithioacetal), pivaloate, adamantoate, crotonate, 4-methoxycrotonate, benzoate, p-phenylbenzoate, 2,4,6-trimethylbenzoate (mesitoate), alkylmethyl carbonate, 9-fluorenylmethyl carbonate (Fmoc), alkyl ethyl carbonate, alkyl 2,2,2-trichloroethyl carbonate (Troc), 2-(trimethylsilyl)ethyl carbonate (TMSEC), 2-(phenylsulfonyl) ethyl carbonate (Psec), 2-(triphenylphosphonio) ethyl carbonate (Peoc), alkyl isobutyl carbonate, alkyl vinyl carbonate alkyl allyl carbonate, alkyl p-nitrophenyl carbonate, alkyl benzyl carbonate, alkyl p-methoxybenzyl carbonate, alkyl 3,4-di methoxybenzyl carbonate, alkyl o-nitrobenzyl carbonate, alkyl p-nitrobenzyl carbonate, alkyl S-benzyl thiocarbonate, 4-ethoxy-1-napththyl carbonate, methyl dithiocarbonate, 2-iodobenzoate, 4-azidobutyrate, 4-nitro-4-methylpentano ate, o-(dibromomethyl)benzoate, 2-formylbenzene sulfonate, 2-(methylthiomethoxy)ethyl, 4-(methylthio methoxy)butyrate, 2-(methylthiomethoxymethyl)benzoate, 2,6-dichloro-4-methylphenoxyacetate, 2,6-dichloro-4-(1 ,1 ,3,3-tetramethylbutyl)phenoxyacetate, 2,4-bis(l, 1 -dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinoate, (E)-2-methyl-2-butenoate, o-(methoxycarbonyl)benzoate, a-naphthoate, nitrate, alkyl N,N,N',N'-tetramethylphosphorodiamidate, alkyl N-phenylcarbamate, borate, dimethylphosphinothioyl, alkyl 2,4-dinitrophenylsulfenate, sulfate, methanesulfonate (mesylate), benzylsulfonate, and tosylate (Ts). For protecting 1 ,2- or 1 ,3- diols, the protecting groups include methylene acetal, ethylidene acetal, 1 -t-butylethylidene ketal, 1 -phenylethyl idene ketal, (4-methoxyphenyl) ethylidene acetal, 2,2,2- trichloroethylidene acetal, acetonide, cyclopentylidene ketal, cyclohexylidene ketal, cycloheptylidene ketal, ben zylidene acetal, p-methoxybenzylidene acetal, 2,4-dimethoxybenzylidene ketal, 3,4-dimethoxybenzylidene acetal, 2-nitrobenzylidene acetal, methoxymethylene acetal, Ethoxymethylene acetal, dimethoxymethylene orthoester, 1-methoxyethylidene orthoester, 1 -ethoxyethylidine orthoester, 1 ,2-dimethoxyethylidene orthoester, a-methoxybenzylidene orthoester, 1-(N,N-dimethylamino)ethylidenederivative, a-(N,N'-dimethylamino)benzylidene derivative, 2-oxacyclopentylidene ortho ester, di-t-butylsilylene group (DTBS), 1 ,3-(1 ,1 ,3,3-tetraisopropyldisiloxanylidene) derivative (TIPDS), tetra-t-butoxydisiloxane-1 ,3-diylidene derivative (TBDS), cyclic carbonates, cyclic boronates, ethyl boronate, or phenyl boronate or other related protecting groups, etc.
[0176] By “an alcohol with a protecting group” is meant an -OH group modified with a protecting group as described herein, for example, OTBS, etc.10102-042W01
[0177] By “dialkylsulfoxonium methylide” is meant a compound having the structure (R4)2SOCH2where R4can be Ci-Ce alkyl e.g., Me, Et, Pr, iPr, Bu, etc.). In some embodiments, a dialkylsulfoxonium methylide is dimethyloxosulfonium methylide.
[0178] By “suitable reagent” is meant a reagent that can be used to react with, for example, deprotect, an ENA intermediate to produce an ENA, as described herein or known in the art. It is to be understood that the skilled person would be able to determine the suitable reagent, based on the selected synthesis.
[0179] In some embodiments, a suitable reagent can be a Bronsted-Lowry acid or a Lewis acid.
[0180] By “Bronsted-Lowry acid” as used herein is meant a compound that can donate a proton (H+) to another compound. A Bronsted-Lowry acid includes without limitation hydrochloric acid (HCI, aqueous), HBr (aqueous), sulfuric acid (H2SO4), Methanesulfonic acid (MsOH), p-Toluenesulfonic acid (p-TsOH), Camphorsulfonic acid (CSA), nitric acid (HNO3), acetic acid (CH3COOH), Dichloroacetic acid, Trichloroacetic acid (CCI3COOH), Trifluoroacetic acid (TFA), Phosphoric acid (H3PO4), Oxalic acid, Citric acid, ammonium ions (NH4+), Pyridinium p-toluenesulfonate (PPTS), Amberlyst-15, Dowex 50W-X8, Montmorillonite K10 clay, etc.
[0181] By “Lewis acid” is meant a compound with vacant orbitals that can accept an electron pair ( / .e., an electrophile). A Lewis acid includes without limitation AICI3, BF3, Fe3+, Zn2+, SO, BF3-OEt2, BCI3, B(C6F5)3, TiCI4, SnCI4, SnBr4, FeCI3, ZnCI2 / ZnBr2, MgBr2-OEt2, TMSOTf, lnCI3 / ln(OTf)3, Sc(OTf)3, Yb(OTf)3, La(OTf)3, Ce(OTf)3 / CeCI3, Bi(OTf)3, Cu(OTf)2, NbCI5, etc.
[0182] A “one-pot” process involves the preparation of an ENA triol compound by formation of an aceton ide-protected (AP) compound from a fluorohydrin and deprotection of the AP compound in the same process using acid and a protic solvent i.e., a solvent that can donate protons.
[0183] In some embodiments, a protic solvent includes without limitation DMF, DCE, DCM, MeCN, THF, Me-THF, DMSO, etc.
[0184] “Optional” or “optionally” means that the subsequently described event of circumstances may or may not occur, and that the description includes instances where the event or circumstance occurs one or more times and instances in which it does not. For example, “optionally substituted alkyl” means that the alkyl group may or may not be substituted and that the description includes both substituted alkyl groups and alkyl groups having no substitution, and that the alkyl groups may be substituted one or more times. Examples of optionally substituted alkyl groups include, without limitation, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, etc. Examples of suitable10102-042W01optional substituents include, without limitation, H, F, Cl, CH3, OH, OCH3, CF3, CHF2, CH2F, CN, halo, and C1-10 alkoxy. Similarly, “optionally substituted aryl- or heteroaryl-“mean aryl- or heteroaryl- groups that may or may not be substituted and that the description includes both substituted aryl- or heteroaryl- groups and aryl- or heteroaryl- groups having no substitution, and that the aryl- or heteroaryl- groups may be substituted one or more times. Examples of suitable optional substituents include, without limitation, H, F, Cl, CH3, OH, OCH3, CF3, CHF2, CH2F, CN, halo, and C1-10 alkoxy.
[0185] In some embodiments, the methods disclosed herein provide rapid access to ENAs in good enantioselectivity and / or yield, for example, greater than about 10g to about 400g, or any value in between, for example 10g, 15g, 20g, 25g, 50g, 75g, 100g, 125g, 150g, 200g, 250g, 300g, 350g, or 400g. Accordingly, the methods disclosed herein can be used in the process scale production of ENAs.
[0186] In some embodiments, the present disclosure includes methods for the synthesis of ENAs, for example, as follows:whereR1and R2can each independently be H, alkyl, acyl, a hydroxyl protecting group, or together can be a cyclic protecting group; andR3can be an optionally substituted aryl or heteroaryl group.10102-042W01
[0187] In some embodiments, the present disclosure includes an exemplary process for the synthesis of ENAs as follows:10 (Het = heteroarene)
[0188] Here, Compound 10, where Het = an optionally substituted aryl or heteroaryl group, is reacted with a dialkylsulfoxonium methylide compound to yield Compound 12. This process invoves the addition of an excess amount of the trimethylsulfoxonium (TMSO) ylide to the ketofluorohydrin of Compound 10.
[0189] Compound 12 can be formed and then deprotected separately by reaction with acid to provide ENA 3. Alternatively, Compound 12 can be deprotected in the same reaction flask using acid and a protic solvent to form ENA 3. Compound 12 can be produced from Compound 10 by formation of an epoxide and opening of the epoxide with TMSO ylide followed by two cyclizations in the same reaction mixture.[16181
[0190] In some embodiments, the synthesis methods disclosed herein may streamline the process of ENA synthesis and reduce manufacturing costs and production time.
[0191] In some embodiments, the methods disclosed herein may be useful as a tool for drug design.
[0192] In some embodiments, the ENA nucleoside analogues disclosed herein may be used as small molecule therapeutics or as monomers in oligonucleotide therapeutics, such as antisense therapy.
[0193] In some embodiments, the methods disclosed herein may be useful in the preparation of diversity libraries. For example, larger collections of ENAs e.g., focused screening libraries) can be generated using the methods described herein.
[0194] As used herein the singular forms “a”, “and”, and “the” include plural referents unless the context clearly dictates otherwise. For example, “a compound” refers to one or more of such compounds. Throughout this application, it is contemplated that the term “compound” or “compounds” refers to the compounds discussed herein and includes precursors and derivatives of the compounds. The compounds of the present invention may contain one or more asymmetric centers and can thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers.10102-042W01Additional asymmetric centers may be present depending upon the nature of the various substituents on the molecule. Each such asymmetric center will independently produce two optical isomers and it is intended that all of the possible optical isomers and diastereomers in mixtures and as pure or partially purified compounds are included within the ambit of this invention, unless specifically indicated otherwise. Any formulas, structures or names of compounds described in this specification that do not specify a particular stereochemistry are meant to encompass any and all existing isomers as described above and mixtures thereof in any proportion. When stereochemistry is specified, the invention is meant to encompass that particular isomer in pure form or as part of a mixture with other isomers in any proportion. Single enantiomers, i.e., optically active forms, can be obtained by asymmetric synthesis or by resolution of the racemates. Resolution of the racemates can be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent; chromatography, using, for example a chiral HPLC column; or derivatizing the racemic mixture with a resolving reagent to generate diastereomers, separating the diastereomers via chromatography, and removing the resolving agent to generate the original compound in enantiomerically enriched form. These procedures can be repeated, if desired, to increase the enantiomeric purity of a compound. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless otherwise specified, it is intended that the compounds include the cis, trans, Z- and E- configurations. Likewise, all tautomeric forms are also intended to be included.
[0195] The starting materials can be obtained from commercial sources, prepared from commercially available organic compounds, prepared using known synthetic methods.
[0196] The present disclosure will be further illustrated in the following examples.
[0197] Examples
[0198] Materials and Methods
[0199] Nuclear magnetic resonance (NMR) spectra were recorded using deuterochloroform (CDCh), deuteromethanol (CD3OD), deuteroacetone ((CD3)2CO), deuteroacetonitrile (CD3CN) or deuterodimethyl sulfoxide (DMSO-cfe) as the solvent. Signal positions (5) are given in parts per million from tetramethylsilane (50) and were measured relative to the signal of the solvent (1H NMR: CDCI3: 67.26; CD3OD: 53.31; (CDs^CO: 5 2.05; CD3CN: 5 1.96; DMSO-cfe: 62.50;13C NMR: CDCI3: 577.16; CD3OD: 549.00;(CD3)2CO: 529.84; CD3CN: 5 1.32; DMSO-cfe: 39.5). Coupling constants (J values) are given in Hertz (Hz) and are reported to the nearest 0.1 Hz.1H NMR spectral data are tabulated in the order: multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; sept, septet; m, multiplet; br broad), coupling constants, number of protons. NMR spectra were recorded on a Bruker10102-042W01Avance 600 equipped with a QNP or TCI cryoprobe (600 MHz), Broker 400 (400 MHz) or Broker 500 (500 MHz). Diastereomeric ratios (dr) are based on analysis of crude1H NMR. Assignments of1H are based on analysis of1H-1H-COSY and nOe spectra. Assignments of13C are based on analysis of HSQC spectra.
[0200] Example 1
[0201] The reaction between trimethylsulfoxonium ylides and Compound 13 was examined in DMF as solvent (Table 1).via extended CCRTable 1. Synthesis of Compound 16.entry conditions % 16 1. TMSOI (10.0 eq.), NaH (3.10 eq.), No NaOH, CsF (1.0 eq.), dry DMF (c = 10 0.1 M), O °C-rt, 48 h2. TMSOI (10.0 eq.), NaH (3.10 eq.), NaOH (1.0 eq.), No CsF, dry DMF (c = 11 0.1 M), O °C-rt, 48 h3. TMSOI (10.0 eq.), K3PO4(3.0 eq.) dry DMF (c = 0.1 M), 0 °C-rt, 48 h 0 4. TMSOI (10.0 eq.), NaH (3.10 eq.), NaOH (1.0 eq.), CsF (1.0 eq.), dry ACN 0 (c = 0.1M), 0 °C-rt, 48 h5. TMSOI (10.0 eq.), NaH (3.10 eq.), NaOH (1.0 eq.), CsF (1 .0 eq.), dry THF 0 (c = 0.1M), 0 °C-rt, 48 h6. TMSOI (5.0 eq.), NaH (3.10 eq.), NaOH (1.0 eq.), CsF (1.0 eq.), dry DMF 9 (c = 0.1M), 0 °C-rt, 48 h7. TMSOI (5.0 eq.), NaH (5.0 eq.), dry DMF (c = 0.1 M), 0 °C-rt, 60 h 8 *8. TMSOI (4.0 eq.), NaH (4.0 eq.), CsF (1.0 eq.) dry DMF (c = 0.1 M), 0 °C-rt, 18 48 h9. TMSOI (4.0 eq.), NaH (4.0 eq.), CsF (1.0 eq.) dry DMSO (c = 0.1 M), 0 °C- 10 rt, 48 h10. TMSOI (4.0 eq.), DBU (4.0 eq.), dry DMF (c = 0.1 M), 0 °C-rt, 48 h 010102-042W0111. TMSOI (4.0 eq.), t-BuOK (4.0 eq.), dry DMF (c = 0.1 M), -40 °C-rt, 60 h 11 *12. TMSOI (4.0 eq.), NaH (4.0 eq.), dry DMF (c = 0.1 M), -40 oC-rt, 60 h 28 13. TMSOI (4.0 eq.), NaH (4.0 eq.), dry DMF (c = 0.1 M), -40 °C-rt, 6 h, then 50 0 °C, 24 h14. TMSOI (4.0 eq.), t-BuOK (4.0 eq.), dry DMF (c = 0.1 M), -40 °C-rt, 60 h 21 15. TMSOI (4.0 eq.), iPrMgCI (4.0 eq.), dry DCM (c = 0.1 M), -78 °C-rt, 24 h 0 16. TMSOCI (4.0 eq.), NaH (4.0 eq.), dry DMF (c = 0.1 M), -40 °C-rt, 24 h 13 17. TMSOBr (4.0 eq.), NaH (4.0 eq.), dry DMF (c = 0.1 M), -40 °C-rt, 60 h 12%
[0202] Example 2
[0203] The initial reaction employed TMSOI (10.0 eq.), NaH (2.0 eq.), NaOH (1.0 eq.), and CsF (1.0 eq.) in dry DMF at room temperature for 72 hours. This reaction yielded 14% of AP-ENA 16 (see Table 1)J171
[0204] Various solvents and bases and equivalents of bases can be used for this process as summarized in Table 1. For example, using TMSOI (4.0 eq.) and NaH (4.0 eq.) in dry DMF at -40°C to room temperature over 60 hours, produces 23% of AP-ENA 16. Other bases such as DBU, t-BuOK, iPrMgCI, and regents TMSOCI, and TMSOBr were also tested under various conditions and also afford the desired ENA. A one-pot process also provides diol 17, achieving a 26% yield (NMR) for ENA 17.
[0205] One step preparation of ENA 17.10102-042W0116 AP-ENA 17 ENA
[0206] A mixture of sodium hydride (60% in oil, 52 mg, 1.26 mmol) and TMSOI (282 mg, 1.26 mmol) was placed in an oven-dried flask and dry DMF (3 mL) was added to the mixture at room temperature. After hydrogen evolution ceased, the milky solution turned clear. The reaction mixture was stirred for 15 min at room temperature and then shifted to -40 °C. Compound 13 (100 mg, 0.316 mmol) was dissolved in dry DMF (0.5 mL), added to the clear solution dropwise in one portion at -40 °C and slowly warm to room temperature. The reaction mixture was stirred for 3 days and then was quenched using 2.0 mL of 1.0 M aq. KH2PO4 and extracted with EtOAc 4 times. The organic extracts were combined, dried over anhydrous sodium sulfate, and concentrated. Afterwards the crude 16 was dissolved in MeOH (1 mL) and TFA (0.13 mL, 1.58 mmol) was added. The reaction was stirred at room temperature for 30 minutes then the solvent was removed under reduced pressure. The crude was then dissolved in methanol again to azeotrope off the TFA this was repeated 3 times. An assay yield was obtained for the deprotected ENA (23.0 mg, 26% over 2 steps) using1H NMR spectroscopy with an internal standard. Purification of an analytical sample by preparative HPLC (2 % ACN / Water to 50 % ACN / Water) afforded 17 as a white powder (9.2 mg, 10%). IR (neat): v = 3201, 2963, 1690, 1462, 1377, 1284, 1197, 1094, 841, 752 cm1; [a]g°= -36.2 (c 0.62 in CH2CI2),1H NMR (500 MHz, MeOD) 58.28 (d, J =f 1.3 Hz, 1 H), 4.10 (d, J = 3.3 Hz, 1 H), 4.05 (d, J = 3.3 Hz, 1 H), 3.98 (m, 2H), 3.75 (d, = 12.3 Hz, 1 H), 3.68 (d, J = 12.4 Hz, 1H), 2.13 (ddd, J = 13.3, 11.6, 7.4 Hz, 1H), 1.87 (d, J = 1.2 Hz, 3H), 1.33 (dd, J = 13.2, 4.3 Hz, 1H);13C NMR 151 MHz, MeOD) 5166.7, 152.0, 137.8, 110.3, 86.7, 85.9, 80.2, 65.8, 62.8, 61.7, 27.9, 12.6;; HRMS (ESI+) calcd for [Ci5H2iFN2O6+H]+345.1456 m / z found: 345.1472 m / z.
[0207] Example 3
[0208] Fluorohydrins 18, 20 and 22 are used to yield the corresponding ENAs 19, 21 and 23, as follows.10102-042W0119PG = suitable protecting groupPG = suitableprotecting group2310102-042W01For Compound 20, the PG can be benzoyl. For Compound 22, the PG can be 2-methylpropionyl. Alternatively, carbamates, acyl groups, silyl groups could also be used as PGs for Compounds 20 or 22.
[0209] References
[0210]
[0001] (a) De Clercq, E. Curr. Opin. Microbiol. 2005, 8 (5), 552-560.
[0211]
[0001] (b) Jordheim, L. P.; Durantel, D.; Zoulim, F.; Dumontet, C. Nat. Rev. Drug Discov. 2013, 12(6), 447-464.
[0212] [2] Ikeda, H.; Fernandez, R.; Barchi, J. J., Jr; Huang, X.; Marquez, V. E.; Wilk, A. Nucleic Acids Res. 1998, 26(9), 2237-2244.
[0213] [3] Seley-Radtke, K. L.; Yates, M. K. Antiviral Res. 2018, 154, 66-86.
[0214] [4] Yates, M. K.; Seley-Radtke, K. L. Antiviral Res. 2019, 162, 5-21.
[0215] [5] (a) Morita, K.; Hasegawa, C.; Kaneko, M.; Tsutsumi, S.; Sone, J.; Ishikawa, T.; Imanishi, T.; Koizumi, M. Nucleic Acids Res. Suppl. 2001, 1, 241-242. (b) Koizumi, M.; Kaneko, M.; Hasegawa, C.; Sone, J.; Imanishi, T.; Morita, K. Nucleic Acids Res. 2001, 29(2), 402-410.
[0216] [6] (a) Koizumi, M.; Ohga, Y.; Akira, K.; Minakuchi, H. Anal. Biochem.2002, 314 (1), 150-152. (b) Morita, K.; Hasegawa, C.; Kaneko, M.; Tsutsumi, S.; Sone, J.; Ishikawa, T.; Imanishi, T.; Koizumi, M. Bioorg. Med. Chem. Lett. 2002, 12(1), 73-76. (c) Morita, K.; Hasegawa, C.; Kaneko, M.; Tsutsumi, S.; Sone, J.; Ishikawa, T.; Imanishi, T.; Koizumi, M. Bioorg. Med. Chem. 2003, 11 (11 ), 2211 -2226.
[0217] [7] (a) Takagi-Sato, M.; Kaneko, M.; Hasegawa, C.; Sone, J.; Imanishi, T.; Koizumi, M. Nucleosides Nucleotides Nucleic Acids 2020, 39(2), 128-144. (b) Koizumi, M. Biol. Pharm. Asp. Nucleic Acids Chem. 2015, 13(2), 201-218.
[0218] [8] Abe, Y.; Ukai, K.; Michida, M. Org. Process Res. Dev. 2022, 26 (5), 904- 913.
[0219] [9] Morita, K.; Kaneko, M.; Hasegawa, C.; Sone, J.; Imanishi, T.; Koizumi, M. Nucleosides Nucleotides Nucleic Acids 2006, 25 (11 ), 1331-1347.
[0220]
[0010] Koizumi, M.; Kaneko, M.; Hasegawa, C.; Sone, J.; Imanishi, T.; Morita, K. Oligonucleotides 2006, 16 (4), 392-401.
[0221]
[0011] Surono, A.; Takeshima, Y.; Wibawa, T.; Ikezawa, M.; Nonaka, I.; Matsuo, M. Hum. Gene Then 2004, 15(8), 739-749.
[0222]
[0012] Yagi, M.; Takeshima, Y.; Surono, A.; Takagi, M.; Koizumi, M.; Matsuo, M. Oligonucleotides 2004, 14 (1), 33-40.
[0223]
[0013] Takagi, M.; Watanabe, T.; Kato, T. Biochemistry 2004, 43(25), 81 OS- SITS.10102-042W01
[0224]
[0014] Varghese, O. P.; Sun, W.; Harada-Shiba, M.; Obika, S. J. Am. Chem. Soc. 2007, 129(3), 580-590.
[0225]
[0015] (a) Meanwell, M.; Silverman, S. M.; Lehmann, J.; Adluri, B.; Wang, Y.; Cohen, R.; Campeau, L.-C.; Britton, R. Science 2020, 569(6504), 725-730. (b) Huxley, C.; Lucas, C.; Bruno, J. M. M.; Anketell, M. J.; Davison, E. K.; Muir, G.; Nodwell, M. B.;Meanwell, M.; Silverman, S. M.; Britton, R.; Campeau, L.-C. Can. J. Chem. 2023, 101 (7), 487-490. (c) Davison, E. K.; Petrone, D. A.; Meanwell, M.; Nodwell, M. B.; Silverman, S. M.; Campeau, L.-C.; Britton, R. Nat. Protoc. 2022, 17(9), 2008-2024.
[0226]
[0016] (a) Corey, E. J.; Chaykovsky, M. J. Am. Chem. Soc. 1962, 84, 3782-3783. (b) Corey, E. J.; Chaykovsky, M. J. Am. Chem. Soc. 1964, 86, 1960-1964.
[0227]
[0017] (a) Butova, E. D.; Barabash, A. V.; Petrova, A. A.; Kleiner, C. M.;Schreiner, P. R.; Fokin, A. A. J. Org. Chem.2010, 75, 6229-6235. (b) Barabash, A. V.;Butova, E. D.; Kanyuk, I. M.; Schreiner, P. R.; Fokin, A. A. J. Org. Chem.2014, 79, 10669-10673.
[0228]
[0018] Fadeev, A. A.; Makarov, A. S.; Ivanova, O. A.; Uchuskin, M. G.;Trushkov, I. V. Org. Chem. Front. 2022, 9, 737-742.
[0229] All citations are hereby incorporated by reference.
[0230] The present invention has been described with regard to one or more embodiments. However, it will be apparent to persons skilled in the art that a number of variations and modifications can be made without departing from the scope of the invention as defined in the claims. Therefore, although various embodiments of the invention are disclosed herein, many adaptations and modifications may be made within the scope of the invention in accordance with the common general knowledge of those skilled in this art. Such modifications include the substitution of known equivalents for any aspect of the invention in order to achieve the same result in substantially the same way. Numeric ranges are inclusive of the numbers defining the range. In the specification, the word “comprising” is used as an open-ended term, substantially equivalent to the phrase “including, but not limited to,” and the word “comprises” has a corresponding meaning. It is to be however understood that, where the words “comprising” or “comprises,” or a variation having the same root, are used herein, variation or modification to “consisting” or “consists,” which excludes any element, step, or ingredient not specified, or to “consisting essentially of” or “consists essentially of,” which limits to the specified materials or recited steps together with those that do not materially affect the basic and novel characteristics of the claimed invention, is also contemplated. The elements of the present invention as described may be indicated specific embodiments, however, it should be understood that they may be combined in any manner and in any number to create additional embodiments. The variously described examples and preferred embodiments should not be construed to limit the present invention to only the10102-042W01explicitly described embodiments. This description should be understood to support and encompass embodiments which combine the explicitly described embodiments with any number of the disclosed and / or preferred elements. Furthermore, any permutations and combinations of all described elements in this application should be considered disclosed by the description of the present application unless the context indicates otherwise. Citation of references herein shall not be construed as an admission that such references are prior art to the present invention. All publications are incorporated herein by reference as if each individual publication was specifically and individually indicated to be incorporated by reference herein and as though fully set forth herein. The invention includes all embodiments and variations substantially as hereinbefore described and with reference to the examples.
Claims
10102-042W01WHAT IS CLAIMED IS:
1. A method of synthesizing an ENA compound or intermediate thereof, the method comprising:i) providing a fluorohydrin compound of the structure:O OHOR1OR2FwhereinR1and R2are each independently H, alkyl, acyl, a hydroxyl protecting group, or together are a cyclic protecting group; andR3is an optionally substituted aryl or heteroaryl group; andii) reacting the fluorohydrin compound with a dialkylsulfoxonium methylide to yield an ENA compound of the structure:OR2whereinR1and R2are each independently H, alkyl, acyl, a hydroxyl protecting group, or together are a cyclic protecting group; andR3is an optionally substituted aryl or heteroaryl group.
2. The method of claim 1 wherein the dialkylsulfoxonium methylide compound is (R4)2SOCH2wherein R4is Ci-C6alkyl.
3. The method of claim 1 wherein the dialkylsulfoxonium methylide compound is dimethyloxosulfonium methylide.
4. The method of any one of claims 1 to 3 wherein R1and R2are each dependently -OH or -OC(CH3)2O-.10102-042W015. The method of any one of claims 1 to 4 wherein the fluorohydrin compound is:O.Z„O FwhereinR3is an optionally substituted aryl or heteroaryl group; andZ is H, alkyl, acyl, a hydroxyl protecting group, or a cyclic protecting group.
6. The method of claim 5 wherein the hydroxyl protecting group is selected from the group consisting of acetonide, silyl protecting group, alkyl protecting group and aryl protecting group.
7. The method of any one of claims 1 to 6 wherein the fluorohydrin compound is:, orwherein PG is a protecting group.
8. The method of any one of claims 1 to 4 comprising:i) providing a fluorohydrin compound of the structure:10102-042W01wherein R3is an optionally substituted aryl or heteroaryl group; andii) reacting the fluorohydrin compound with a dialkylsulfoxonium methylide to yield an ENA intermediate compound of the structure:wherein R3is an optionally substituted aryl or heteroaryl group.
9. The method of any one of claims 1 to 4 comprising:i) providing an ENA intermediate compound of the structure:owherein R3is an optionally substituted aryl or heteroaryl group; andii) reacting the ENA intermediate compound with a suitable reagent, to yield an ENA triol compound of the structure:OHwherein R3is an optionally substituted aryl or heteroaryl group.
10. A method of synthesizing an ethylene-bridged nucleic acid (ENA) triol compound, the method comprising:10102-042W01i) providing an ENA intermediate compound of the structure:wherein R3is an optionally substituted aryl or heteroaryl group; andii) reacting the ENA intermediate compound with a suitable reagent, to yield an ENA triol compound of the structure:OHwherein R3is an optionally substituted aryl or heteroaryl group.
11. The method of claim 9 or 10 wherein the suitable reagent is a Bronsted-Lowry acid or a Lewis acid.
12. The method of claim 11 wherein the Bronsted-Lowry acid is (HCI, aqueous), HBr (aqueous), sulfuric acid (H2SO4), Methanesulfonic acid (MsOH), p-Toluenesulfonic acid (p-TsOH), Camphorsulfonic acid (CSA), nitric acid (HNO3), acetic acid (CH3COOH), Dichloroacetic acid, Trichloroacetic acid (CCI3COOH), Trifluoroacetic acid (TEA), Phosphoric acid (H3PO4), Oxalic acid, Citric acid, ammonium ions (NH4+), Pyridinium p-toluenesulfonate (PPTS), Amberlyst-15, Dowex 50W-X8, or Montmorillonite K10 clay.
13. The method of claim 11 wherein the Lewis acid is AICI3, BF3, Fe3+, Zn2+, SO, BF3-OEt2, BCI3, B(C6FS)3, TiCI4, SnCI4, SnBr4, FeCI3, ZnCI2 / ZnBr2, MgBr2-OEt2, TMSOTf, lnCI31 ln(OTf)3, Sc(OTf)3, Yb(OTf)3, La(OTf)3, Ce(OTf)31 CeCI3, Bi(OTf)3, Cu(OTf)2, or NbCI5.
14. The method of any one of claims 1 to 6 and 8 to 13 wherein R3is an optionally substituted purine or an optionally substituted pyrimidine group.
15. The method of any one of claims 1 to 6 and 8 to 14 wherein R3is an optionally substituted purine-9-yl or an optionally substituted 2-oxo-l,2-dihydropyrimidine-l-yl group.10102-042W0116. The method of any one of claims 8 to 15 wherein the ENA intermediate compound is:
17. The method of any one of claims 1 to 16 wherein the ENA compound is of the structure:10102-042W01 18. A compound of the structure:
